Cargando…

Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals

BACKGROUND: Predicting progression to clinical arthritis in individuals at-risk of developing rheumatoid arthritis is a prerequisite to developing stratification groups for prevention strategies. Selecting accurate predictive criteria is the critical step to define the population at-risk. While posi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponchel, Frederique, Duquenne, Laurence, Xie, Xuanxiao, Corscadden, Diane, Shuweihdi, Farag, Mankia, K, Trouw, L A, Emery, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764647/
https://www.ncbi.nlm.nih.gov/pubmed/36535711
http://dx.doi.org/10.1136/rmdopen-2022-002512
_version_ 1784853316280254464
author Ponchel, Frederique
Duquenne, Laurence
Xie, Xuanxiao
Corscadden, Diane
Shuweihdi, Farag
Mankia, K
Trouw, L A
Emery, Paul
author_facet Ponchel, Frederique
Duquenne, Laurence
Xie, Xuanxiao
Corscadden, Diane
Shuweihdi, Farag
Mankia, K
Trouw, L A
Emery, Paul
author_sort Ponchel, Frederique
collection PubMed
description BACKGROUND: Predicting progression to clinical arthritis in individuals at-risk of developing rheumatoid arthritis is a prerequisite to developing stratification groups for prevention strategies. Selecting accurate predictive criteria is the critical step to define the population at-risk. While positivity for anti-citrullinated protein antibodies (ACPA) remains the main recruitment biomarker, positivity for other autoantibodies (AutoAbs) identified before the onset of symptoms, may provide additional predictive accuracy for stratification. OBJECTIVE: To perform a multiple AutoAbs analysis for both the prediction and the time of progression to inflammatory arthritis (IA). METHODS: 392 individuals were recruited based on a new musculoskeletal complaint and positivity for ACPA or rheumatoid factor (RF). ELISAs were performed for ACPA, RF, anti-nuclear Ab, anti-carbamylated protein (anti-CarP) and anti-collagen AutoAbs. Logistic and COX regression were used for analysis. RESULTS: Progression to IA was observed in 125/392 (32%) of cases, of which 78 progressed within 12 months. The AutoAbs ACPA, RF, anti-CarP were individually associated with progression (p<0.0001) and improved prediction when combined with demographic/clinical data (Accuracy >77%; area under the curve (AUC) >0.789), compared with prediction using only demographic/clinical data (72.9%, AUC=0.760). Multiple AutoAbs testing provided added value, with +6.4% accuracy for number of positive AutoAbs (AUC=0.852); +5.4% accuracy for AutoAbs levels (ACPA/anti-CarP, AUC=0.832); and +6.2% accuracy for risk-groups based on high/low levels (ACPA/RF/anti-CarP, AUC=0.837). Time to imminent progression was best predicted using ACPA/anti-CarP levels (AUC=0.779), while the number of positive AutoAbs was/status/risk were as good (AUC=0.778). CONCLUSION: We confirm added value of multiple AutoAbs testing for identifying progressors to clinical disease, allowing more specific stratification for intervention studies.
format Online
Article
Text
id pubmed-9764647
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-97646472022-12-21 Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals Ponchel, Frederique Duquenne, Laurence Xie, Xuanxiao Corscadden, Diane Shuweihdi, Farag Mankia, K Trouw, L A Emery, Paul RMD Open Rheumatoid Arthritis BACKGROUND: Predicting progression to clinical arthritis in individuals at-risk of developing rheumatoid arthritis is a prerequisite to developing stratification groups for prevention strategies. Selecting accurate predictive criteria is the critical step to define the population at-risk. While positivity for anti-citrullinated protein antibodies (ACPA) remains the main recruitment biomarker, positivity for other autoantibodies (AutoAbs) identified before the onset of symptoms, may provide additional predictive accuracy for stratification. OBJECTIVE: To perform a multiple AutoAbs analysis for both the prediction and the time of progression to inflammatory arthritis (IA). METHODS: 392 individuals were recruited based on a new musculoskeletal complaint and positivity for ACPA or rheumatoid factor (RF). ELISAs were performed for ACPA, RF, anti-nuclear Ab, anti-carbamylated protein (anti-CarP) and anti-collagen AutoAbs. Logistic and COX regression were used for analysis. RESULTS: Progression to IA was observed in 125/392 (32%) of cases, of which 78 progressed within 12 months. The AutoAbs ACPA, RF, anti-CarP were individually associated with progression (p<0.0001) and improved prediction when combined with demographic/clinical data (Accuracy >77%; area under the curve (AUC) >0.789), compared with prediction using only demographic/clinical data (72.9%, AUC=0.760). Multiple AutoAbs testing provided added value, with +6.4% accuracy for number of positive AutoAbs (AUC=0.852); +5.4% accuracy for AutoAbs levels (ACPA/anti-CarP, AUC=0.832); and +6.2% accuracy for risk-groups based on high/low levels (ACPA/RF/anti-CarP, AUC=0.837). Time to imminent progression was best predicted using ACPA/anti-CarP levels (AUC=0.779), while the number of positive AutoAbs was/status/risk were as good (AUC=0.778). CONCLUSION: We confirm added value of multiple AutoAbs testing for identifying progressors to clinical disease, allowing more specific stratification for intervention studies. BMJ Publishing Group 2022-12-19 /pmc/articles/PMC9764647/ /pubmed/36535711 http://dx.doi.org/10.1136/rmdopen-2022-002512 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Rheumatoid Arthritis
Ponchel, Frederique
Duquenne, Laurence
Xie, Xuanxiao
Corscadden, Diane
Shuweihdi, Farag
Mankia, K
Trouw, L A
Emery, Paul
Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals
title Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals
title_full Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals
title_fullStr Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals
title_full_unstemmed Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals
title_short Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals
title_sort added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals
topic Rheumatoid Arthritis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764647/
https://www.ncbi.nlm.nih.gov/pubmed/36535711
http://dx.doi.org/10.1136/rmdopen-2022-002512
work_keys_str_mv AT ponchelfrederique addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals
AT duquennelaurence addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals
AT xiexuanxiao addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals
AT corscaddendiane addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals
AT shuweihdifarag addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals
AT mankiak addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals
AT trouwla addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals
AT emerypaul addedvalueofmultipleautoantibodytestingforpredictingprogressiontoinflammatoryarthritisinatriskindividuals